The largest vaccine manufacturers in the world have struggled with meeting demands, but it is to their credit, including that of @SerumInstIndia @BharatBiotech @pfizer Moderna, J&J & others, that they have, for domestic mkts and more, met even what they have, in these conditions https://twitter.com/chadbown/status/1391007406080077825

Would revisiting the TRIPS waiver have helped? Possibly, if done much earlier, by spreading the manufacturing process out. But that still leaves us with the question of capacity. This was unprecedented, the scale and the speed, and safe to say, what could be done has been done

Across the globe, in Europe, in the US, in India and in SA. It may be worth revisiting the TRIPS waiver more for future crises like this, and with more stakeholder engagement to find a more ideal balance and alignment of interests.

At this point, I’m not sure how much business sense it makes for manufacturers to not share licenses as needed, and have vaccines mass administered anymore. Do Moderna & others not want the market Astrazeneca is accessing through SII, for eg? I doubt it!

At this point in the #Covid19 situation, it may be down to reasonable expectations on vaccine production capacity, and taking our shots, as citizens, as and when they’re due. Yes we need more vaccines quickly. But being reasonable is important too.

More than anything, remembering that it’s not over for anyone till its over for everyone, so cooperating to vaccinate everyone. Doing what is needed to make sure that happens. Universal access to the vaccine. With or without a TRIPS waiver.

So much that trade policy can contribute to for future crises, and this thread by @ChadBown adds another perspective to a very engaging discussion (ref: the s by @VidigalGeraldo @mercuriobryan and @kashidih that offer very interesting analysis)